CA2477119A1 - Compounds that modulate the activity of ptp-1b and tc-ptp - Google Patents

Compounds that modulate the activity of ptp-1b and tc-ptp Download PDF

Info

Publication number
CA2477119A1
CA2477119A1 CA002477119A CA2477119A CA2477119A1 CA 2477119 A1 CA2477119 A1 CA 2477119A1 CA 002477119 A CA002477119 A CA 002477119A CA 2477119 A CA2477119 A CA 2477119A CA 2477119 A1 CA2477119 A1 CA 2477119A1
Authority
CA
Canada
Prior art keywords
ptp
compound
exosite
hydrogen
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002477119A
Other languages
English (en)
French (fr)
Inventor
Kenneth Barr
Bruce Fahr
Stig Hansen
Christian Wiesmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viracta Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2477119A1 publication Critical patent/CA2477119A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002477119A 2002-03-01 2003-02-26 Compounds that modulate the activity of ptp-1b and tc-ptp Abandoned CA2477119A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36147502P 2002-03-01 2002-03-01
US60/361,475 2002-03-01
US10/374,539 US6784205B2 (en) 2002-03-01 2003-02-25 Compounds that modulate the activity of PTP-1B and TC-PTP
US10/374,539 2003-02-25
PCT/US2003/005950 WO2003073987A2 (en) 2002-03-01 2003-02-26 Compounds that modulate the activity of ptp-1b and tc-ptp

Publications (1)

Publication Number Publication Date
CA2477119A1 true CA2477119A1 (en) 2003-09-12

Family

ID=27791680

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002477119A Abandoned CA2477119A1 (en) 2002-03-01 2003-02-26 Compounds that modulate the activity of ptp-1b and tc-ptp

Country Status (6)

Country Link
US (2) US6784205B2 (https=)
EP (1) EP1534264A4 (https=)
JP (1) JP2005526051A (https=)
AU (1) AU2003217766A1 (https=)
CA (1) CA2477119A1 (https=)
WO (1) WO2003073987A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
US6974681B1 (en) * 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
CA2551909C (en) * 2004-02-12 2011-10-11 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
WO2006009876A2 (en) * 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
WO2006028970A1 (en) * 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
NZ569329A (en) 2006-01-30 2011-09-30 Transtech Pharma Inc Substituted imidazole derivatives and their use as PTPase inhibitors
WO2009091609A1 (en) * 2008-01-18 2009-07-23 Genaera Corporation A method for treating rapamycin induced diabetes-like syndrome using trodusquemine
US9217012B2 (en) 2009-04-08 2015-12-22 Indiana University Research And Technology Corporation Inhibitors of protein tyrosine phosphatases
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2014113407A2 (en) * 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
US10618932B2 (en) 2017-02-21 2020-04-14 Arizona Board Of Regents On Behalf Of Arizona State University Method for targeted protein quantification by bar-coding affinity reagent with unique DNA sequences

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703407B1 (en) * 1994-09-20 2004-03-09 Eli Lilly And Company Benzofuran compounds, compositions, and methods
JP2002514636A (ja) * 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン抵抗性または高血糖症の治療に有用なフェニルオキソ−酢酸類
US6498151B2 (en) * 2000-03-22 2002-12-24 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
AU2001268951A1 (en) * 2000-07-07 2002-01-21 Novo-Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)

Also Published As

Publication number Publication date
WO2003073987A3 (en) 2005-03-31
JP2005526051A (ja) 2005-09-02
WO2003073987A2 (en) 2003-09-12
AU2003217766A1 (en) 2003-09-16
US20040147596A1 (en) 2004-07-29
EP1534264A2 (en) 2005-06-01
EP1534264A4 (en) 2007-06-13
US6784205B2 (en) 2004-08-31
US20030195247A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
US6784205B2 (en) Compounds that modulate the activity of PTP-1B and TC-PTP
US6376529B1 (en) Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
WO1999046232A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
US10392389B2 (en) Heterocyclic compounds for the inhibition of PASK
MX2012005342A (es) Uso de derivados benzo-heterociclico para prevenir y tratar el cancer o para inhibir metastasis de cancer.
JP2009526034A (ja) デュシェンヌ型筋ジストロフィーの治療
AU2017309751B2 (en) Sulfonamides as GPR40- and GPR120-agonists
EP1419770A1 (en) Apo ai expression accelerating agent
CA2522225A1 (en) Carboxamide derivatives as anti-diabetic agents
US6114386A (en) Inhibitors of bacterial sialidase
KR20090031333A (ko) 신규한 베타-세크리타제 저해용 화합물
US9085566B2 (en) Compositions and methods for the treatment of metabolic and related disorders
WO2000023442A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
WO2000033837A2 (en) Myt1 kinase inhibitors
WO2006127379A2 (en) Par2-modulating compounds and their use
KR20010072871A (ko) 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
US6391894B1 (en) Myt1 kinase inhibitors
US6642263B2 (en) Modulators of Rho C activity
US20030134862A1 (en) Compounds
KR20220148851A (ko) 신규한 매크로사이클릭 화합물, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물
JP2023518299A (ja) 小分子エナンチオマーによるアンドロゲン受容体調節
CN101130526B (zh) 用作治疗剂的芳基羰基衍生物
US6800634B2 (en) Modulators of Rho C activity
WO2000033841A1 (en) Myt1 kinase inhibitors
KR20130108876A (ko) Ｓｈｐ－2의 활성을 특이적으로 저해하는 조성물 및 이의 제조방법

Legal Events

Date Code Title Description
FZDE Dead